Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06570213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Study sites: 0 to 1
    v7
  2. Minor Re-verified, no change to tracked fieldsv6
  3. Notable Start date: Sep 1, 2025 to Apr 1, 2026v5
  4. Notable Start date: Jun 1, 2025 to Sep 1, 2025v4
  5. Notable Primary and study completion dates: Dec 31, 2028 to Dec 31, 2029
    • Start date: Oct 1, 2024 to Jun 1, 2025
    v3
  6. Minor Study title shortened, about 4 wordsv2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain. The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.
Trial Details
NCT Number NCT06570213
Lead Sponsor Rush University Medical Center
Conditions
(from sponsor)
PTSD
Related terms Stress Disorders, Post-Traumatic
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov